Status:
UNKNOWN
Study to Evaluate the Safety of Nanoxel M Inj.
Lead Sponsor:
Samyang Biopharmaceuticals Corporation
Conditions:
Breast Cancer
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Study to evaluate the safety of Nanoxel M inj. administration in patients.
Detailed Description
This is a multi-center, prospective observational study to observe the incidence of adverse events under actual clinical settings to test the safety of Nanoxel-M inj. administration in patients with b...
Eligibility Criteria
Inclusion
- Adults ≥18 years old
- Patients who have signed written consent form prior to participating in the clinical trial
- Patients who are assessed as adequate to administer Nanoxel M injection.
Exclusion
- 1\) Patients who have shown severe hypersensitivity to Docetaxel and concomitant drugs
Key Trial Info
Start Date :
September 18 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2024
Estimated Enrollment :
1498 Patients enrolled
Trial Details
Trial ID
NCT04066335
Start Date
September 18 2019
End Date
August 1 2024
Last Update
December 18 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samyang Biopharmaceuticals
Seoul, South Korea